Annual Report pertaining to FY 2025-26

August 18, 2026 The Manager The Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Hirose Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub.: Annual Report FY 2025-26 and Notice of the 58th Annual General Meeting (“AGM”) of Blue Jet Healthcare Limited (“the Company”) Dear Sir/ Ma’am, In reference to our earlier letters dated August 3, 2026 and Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Annual Report for the financial year 2025-26 along with the Notice of the 58th Annual General Meeting of the Company scheduled to be held on Monday, September 21, 2026, at 11:00 A.M. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The said Annual Report along with the Notice of the AGM, is being sent through electronic mode to all the Members of the Company whose e‐mail addresses are registered with the Company/ Depository Participant(s). Further, a letter providing the web‐link to access the Annual Report and the Notice of the AGM are being sent to those Members who have not registered their email address. The Annual Report along with the Notice of the AGM is also available on the Company’s website at https://bluejethealthcare.com/annual-report-2/ We request you to take the same on your records. Thanking You, For BLUE JET HEALTHCARE LIMITED Sweta Poddar Company Secretary & Compliance Officer (M. No: F12287) Encl.: as above Partnering with PURPOSE Delivering with PRECISION Progressing with CONFIDENCE Annual Report 2025-26 What lies AHEAD… 01 40 CORPORATE OVERVIEW STATUTORY REPORTS 02 Key Highlights 40 Management Discussion and Analysis 04 Company Snapshot 06 Growth Enablers 50 Board’s Report 08 Our Journey 69 Corporate Governance Report 10 Message from the Chairman 96 Business Responsibility & Sustainability Report 12 Managing Director’s Message 14 Financial Performance 16 Manufacturing Excellence 18 Research and Development 166 20 Quality Focus 22 Product Categories Overview FINANCIAL STATEMENTS 28 Building the Future, Celebrating Excellence 29 Awards 30 Our People 32 Environment, Health and Safety 36 Board of Directors 37 Management Team AGM NOTICE 39 Corporate Information To view this report online and to know more about us, please visit: www.bluejethealthcare.com Partnering with BLUE JET HEALTHCARE IS ON THE PATH OF TRANSITION – EVOLVING FROM A RELIABLE PURPOSE. SERVICE PROVIDER INTO A STRATEGIC CDMO PARTNER, BRINGING PURPOSE, PRECISION Delivering with AND MOMENTUM TO EVERY STAGE OF DRUG PRECISION. DEVELOPMENT AND MANUFACTURING. AS WE STRENGTHEN OUR POSITION AS A Progressing with TRUSTED CDMO, WE CONTINUE TO INVEST IN CONFIDENCE. RESEARCH AND DEVELOPMENT, EXPAND OUR MANUFACTURING FOOTPRINT, AND BUILD ADVANCED CAPABILITIES THAT EMPOWER US TO MEET THE EVOLVING NEEDS OF GLOBAL HEALTHCARE. Our strategic approach is anchored in partnering with purpose, driving sustained success by working closely with our customers to develop solutions designed to create long-term value. Our multi-year, strategic collaborations with multinational innovators and formulation manufacturers promote customer stickiness by minimising supply chain disruption risks and lowering development costs for partners. Our customer relationships are rooted in shared goals: faster timelines, enhanced quality, and patient-centric solutions. By delivering with precision, we demonstrate our relentless focus on quality, reliability, and operational excellence across every stage of the customer value chain. Our disciplined execution approach, combined with our deep technical expertise, enables consistent delivery of products and solutions aligned to the highest global standards. Driven by our ability to identify customer needs, we progress with confidence to capture the momentum of the long-term growth opportunities across our business segments. Our strategic investments in expanding manufacturing capacity, strengthening R&D capabilities, developing a robust talent pool, and scaling digitalisation are steering our evolution into a stronger, more agile, and innovation-driven CDMO partner. They position us to support increasingly complex customer requirements while driving sustainable growth for the years ahead. As we move forward, we remain dedicated to building enduring partnerships, delivering with meticulousness, and powering ahead with optimism towards a future of shared success. We believe our “Collaboration, Development, Manufacturing” approach has been, and will continue to be, critical to our success and a key factor for growing our CDMO business. Blue Jet Healthcare Ltd. | Annual Report 2025-26 KEY HIGHLIGHTS FY 2025-26 in a NUTSHELL OPERATIONAL HIGHLIGHTS Entered into an agreement for sale of Successfully went live with launch of land with the Andhra Pradesh Industrial 1.0 of SAP S/4HANA, as part of a major Infrastructure Corporation Limited for business digital transformation initiative the purchase of an industrial land parcel called "PROJECT LEAP” measuring 102.48 acres at, Rambilli, Anakapalli District, Andhra Pradesh for a consideration Company has raised funds of 8,000 million of ₹435.02 million. Company has initiated through allotment of 15,810,276 equity shares project activities including seeking the under Qualified Institutional Placement on approvals / licenses required for setting up of July 9, 2026, and consequently complied with a manufacturing facility. minimum public shareholding requirements. Secured leasehold premises for an additional R&D centre in Hyderabad. The R&D centre would focus on emerging technologies including intermediates for glucagon-like peptide-1 (“GLP-1”) and other chronic therapies, peptide chemistry, bio-catalysis, and enhanced turnaround for CDMO-tailored late-phase request for proposals Backward integration project at Mahad facility (Unit III) well on track Company was assigned CARE A1+ Short-term and CARE A+ Long-term by the Care Ratings Limited for its long-term/ short-term bank facilities; Securities with this rating are considered to have very strong degree of safety regarding timely payment of financial obligations CORPORATE OVERVIEW FINANCIAL HIGHLIGHTS 9,473 2,941 31% million million Revenue from Operations EBITDA EBITDA Margin 2,478 26% 14.29 million PAT PAT Margin EPS ESG HIGHLIGHTS ENVIRONMENTAL SOCIAL GOVERNANCE ~40% 44.50 37.5% million Savings in energy cost CSR Spend Women members on the from renewable sources Board of Directors Blue Jet Healthcare Ltd. | Annual Report 2025-26 COMPANY SNAPSHOT Partnering to GROW AND EXPAND A specialty pharmaceutical and healthcare ingredient and intermediate company, Blue Jet Healthcare Limited (‘Blue Jet’/’the Company’) offers niche products to innovator pharmaceutical companies and multi-national generic pharmaceutical companies. As a fully integrated CDMO, driven by long-standing collaborations with global pharmaceutical companies, Blue Jet has emerged as a reliable partner for delivering complex, highly technical and sustainable solutions worldwide. Backed by nearly six decades of industry expertise and strong research & development (R&D) capabilities, the Company specialises in the development and manufacturing of contrast media intermediates, pharma intermediates, and APIs and Sweeteners, including saccharin and its salts. Blue Jet manufactures a range of products in-house, including the key starting intermediate and advanced intermediates, which allows us to control our production process for consistent quality and cost effectiveness. Established in 1968, Blue Jet has relentlessly pursued innovation with purpose, maintaining a customer-first approach to cater to the evolving needs of diverse segments globally. Our state-of-the-art manufacturing facilities, with regulatory accreditations, ensure the high [Showing first 8,000 characters — download PDF for full document]